Loading...
PROF
XNAS
Market cap233mUSD
Nov 20, Last price  
6.38USD
1D
-3.19%
1Q
-6.04%
Jan 2017
-19.82%
IPO
-37.36%
Name

Profound Medical Corp

Chart & performance

D1W1MN
XNAS:PROF chart
P/E
—
P/S
14.27
EPS
—
Vol. 1Y
69.82%
Shs. 5Y
11.82%
Rev. 5Y
17.53%
Div Yld LY
—
Div Yld TTM
—
Revenues
16m
+61.10%
000004,904,5501,910,5874,174,0007,304,0006,873,0006,681,0007,199,00010,167,21316,379,804
Net income
-43m
L+63.57%
-9,006,672-14,094,424-8,204,409-11,800,719-12,146,989-14,968,065-15,244,149-15,222,000-21,622,000-30,699,000-28,669,000-28,569,000-26,480,451-43,315,210
CFO
-39m
L+65.76%
-3,012,780-3,169,619-2,879,149-4,943,619-10,789,573-14,854,460-13,431,889-15,446,649-20,574,000-22,360,000-25,800,000-22,609,000-23,453,000-38,875,833

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Key people

Chairman of the Board, Chief Executive Officer · since 2018
Mathieu Burtnyk
President · since 2024
Rashed Dewan
Chief Financial Officer · since 2022
Tom Tamberrino
Chief Commercial Officer · since 2024
Brian Ellacott
Non-Executive Independent Director · since 2019
Cynthia Lavoie
Non-Executive Independent Director · since 2021
Murielle Lortie
Non-Executive Independent Director · since 2020
Arthur Rosenthal
Non-Executive Independent Director · since 2019
Kris Shah
Non-Executive Independent Director · since 2022
IPO date
Sep 24, 2014
Employees
131
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT